Fluorescence-Guided Resection of Malignant Gliomas

Oct 17, 2017 by in NEUROLOGY Comments Off on Fluorescence-Guided Resection of Malignant Gliomas

Fig. 6.1 Scheme illustrating the nature of fluorescence and how it is visualized A Brief History Historically, the use of a fluorophore for highlighting malignant glioma tissue was first described by…

read more

Personalized Medicine Through Advanced Genomics

Oct 17, 2017 by in NEUROLOGY Comments Off on Personalized Medicine Through Advanced Genomics

Fig. 3.1 Cost of sequencing a single human genome. Sequencing costs have fallen rapidly over the past five years as next-generation technologies become increasingly efficient. Graph is reproduced using data from…

read more

Immunotherapy for High-Grade Gliomas

Oct 17, 2017 by in NEUROLOGY Comments Off on Immunotherapy for High-Grade Gliomas

NIH clinical trial Type Phase Eligibility criteria Primary outcome Dosing regimen Treatment groups NCT02311920 Checkpt 1 Newly diagnosed GBM Maximum safe dose In addition to TMZ, Arm I receives anti-CTLA4…

read more

Glioblastoma

Oct 17, 2017 by in NEUROLOGY Comments Off on Glioblastoma

Fig. 18.1 Survival rates of glioblastoma patients by age groups [1] Endogenous Risk Factors The cell of origin of glioblastoma is thought to be a neural stem cell (Box 18.1), but risk…

read more

Targeted Therapy of IDH1-Mutated Tumors

Oct 17, 2017 by in NEUROLOGY Comments Off on Targeted Therapy of IDH1-Mutated Tumors

Fig. 10.1 Molecular mechanisms of IDH-associated tumorigenesis. Wild-type IDH1/2 (wtIDH1/2) converts isocitrate (generated through the citric acid (TCA) cycle) into α-KG, producing NADPH in the process. Mutant IDH1/2 (mutIDH1/2) converts isocitrate…

read more
Get Clinical Tree app for offline access